New registry tracks Odevixibat's Long-Term impact on rare liver disease
NCT ID NCT07185919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry will follow 10 people with progressive familial intrahepatic cholestasis (PFIC) in South Korea who are taking odevixibat (Bylvay). The goal is to see how safe and effective the drug is over the long term in real-world use. Researchers will track side effects and how long patients go without needing surgery or a liver transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
odevixibat (Bylvay)
What this could lead to
If successful, this registry could confirm that odevixibat is safe and effective for long-term use in PFIC patients, supporting its continued use as a treatment option.
What could go wrong
This is a small registry (10 people) in one country, not a controlled trial. It tracks real-world use, so results may not prove cause and effect or apply to all PFIC patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pusan National University Yangsan Hospital
RECRUITINGGyeongsang, South Korea
-
Seoul National University Hospital
ACTIVE_NOT_RECRUITINGSeoul, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea